Bill > HR4005

This bill, the Naloxone Affordability Act of 2023, directs the Comptroller General of the United States to conduct a study on actions that can be taken to ensure appropriate access and affordability of naloxone, a medication used to reverse opioid overdoses. The study will examine the coverage of naloxone under various health insurance plans, including Medicare and Medicaid, the out-of-pocket costs for consumers to purchase naloxone with or without a prescription or coverage, and other factors that impact the coverage and availability of naloxone. The Comptroller General is required to submit a report to Congress with the findings of the study within two years of the bill's enactment.